RICHMOND, British Columbia, July 18, 2006 (PRIMEZONE) -- BioCurex Inc. (Pink Sheets:BOCX) announced today that it will be presenting results obtained with its RECAF(tm) blood test at the American Association for Clinical Chemistry (AACC) Annual Meeting being held in Chicago on July 23-27, 2006.
The presentation will focus on results obtained with the Company's RECAF test of serum samples from normal individuals, prostate cancer patients and patients with benign prostate lesions.
The main problem in prostate cancer diagnosis is not to discriminate patients with cancer from normal individuals, but rather to discriminate between prostate cancer and benign prostate conditions. In this set of samples, which comprised sera from 100 known cancer patients and 30 patients with benign lesions, the standard PSA test showed a sensitivity of 48% with 60% specificity. This means that the test missed over half the cancers (100-48=52) and that 40% (100-60) of the patients were subjected to an unnecessary biopsy of their prostate. Adding a second variant of the test called "free PSA", the specificity was increased to 70% at the expense of doubling the cost. This also meant that 30% of patients with benign lesions would still be unnecessarily subjected to a biopsy.
Using the company's RECAF test on the same cancer and benign samples, the sensitivity was 90% with a specificity of 84%. When the cancer samples were compared with samples from normal individuals, both the sensitivity and the specificity of the RECAF test approached 100%.
About the AACC:
The AACC is an international scientific/medical society of clinical laboratory professionals, physicians, research scientists and other individuals involved with clinical chemistry and clinical laboratory science disciplines. Founded in 1948, the society has 9,500 members and is headquartered in Washington, DC.
The AACC's annual scientific meeting and technology exposition is the leading event in the clinical laboratory profession, attracting 17,000 participants from 110 countries in 2005. The Clinical Laboratory Exposition is the largest exposition in the world, dedicated exclusively to clinical laboratory science, with over 1,600 booths and more than 600 participating organizations attending last year.
For further information about on the AACC visit: www.aacc.org
About BioCurex:
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.
BioCurex has signed a licensing agreement with Abbott Laboratories for BioCurex's RECAF(tm) Cancer technology as outlined in a joint press release dated March 29, 2005. The release noted that the cancer marker RECAF(tm) has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.
To read more about the Company, please visit the News section in our web site (www.biocurex.com).
Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.